Synergetic impact of lipoprotein(a) and fibrinogen on stroke in coronary artery disease patients

Abstract

AbstractBackgroundEmerging data suggested that lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. Previous studies indicated fibrinogen (Fib) had synergetic effect on Lp(a)‐induced events. However, combined impact of Fib and Lp(a) on ischemic stroke has not been elucidated.MethodsIn this prospective study, we consecutively enrolled 8263 patients with stable coronary artery diseases (CAD) from 2011 to 2017. Patients were categorized into three groups according to tertiles of Lp(a) levels [Lp(a)‐low, Lp(a)‐medium, and Lp(a)‐high] and further divided into nine groups by Lp(a) and Fib levels. All subjects were followed up for the occurrence of ischemic stroke.ResultsDuring a median follow‐up of 37.7 months, 157 (1.9%) ischemic strokes occurred. Stroke incidence increased by Lp(a) (1.1 vs. 2.1 vs. 2.5%, Cochran‐Armitage p < .001) and Fib (1.1 vs. 2.0 vs. 2.6%, Cochran‐Armitage p < .001) categories. When further classified into nine groups by Lp(a) and Fib levels, the incidence of ischemic stroke in group 9 [Lp(a)‐high and Fib‐high] was significantly higher than that in group 1 [Lp(a)‐low and Fib‐low] (3.1 vs. 6%, p < .001). The group 9 was associated with a highest risk for ischemic stroke (adjusted HR 4.907, 95% CI: 2.154–11.18, p < .001), compared with individuals in the Lp(a)‐high (adjusted HR 2.290, 95% CI: 1.483–3.537, p < .001) or Fib‐high (adjusted HR 1.184, 95% CI: 1.399–3.410, p = .001). Furthermore, combining Lp(a) with Fib increased C‐statistics by .045 (p = .004).ConclusionsCurrent study first demonstrated that elevated Lp(a) combining with Fib evaluation enhanced the risk of ischemic stroke in patients with CAD beyond Lp(a) or Fib alone.